Publications
Central monoamine dysfunction in Prader-Willi syndrome: a mechanistic framework for core clinical features
The review examines how alterations in serotonin, dopamine and norepinephrine may contribute to the complex features of Prader-Willi syndrome (PWS). These systems help regulate appetite, reward, emotional responses, behavioural control, sleep and arousal, making them relevant to many of the challenges experienced by people living with PWS.
Bringing together findings from human studies, brain imaging, genetics, epigenetics and experimental models, the article explores the biological links between the genetic changes underlying PWS and its clinical features. It also reviews clinical experience with medicines that affect monoamine signalling, including reported benefits and differences in individual responses.
Authored by Sarah Sheldrick, John Maki, Jill Rasmussen, Lois Rosenberger and Shuang Liu, the publication contributes to the scientific rationale underpinning ConSynance’s interest in monoamine-targeted approaches for PWS.
Pubmed link here
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human
Phase 1 SAD results demonstrated that CSTI-500, a potent triple monoamine reuptake inhibitor (TRI), achieves substantial striatal SERT occupancy and moderate DAT occupancy in healthy subjects. Combined with a favorable safety, tolerability, and pharmacokinetic profile, these findings strongly support the continued clinical development of CSTI-500.
Pubmed link here